GlassScriptPhysician profile
Tamara M Burdi
NPI 1568578276
$756.35
in general payments reported to CMS, 2019-2025
14 companies · $89.36 in 2025
The $89.36 reported for 2025 was less than what a typical Obstetrics & Gynecology (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $211 · 2022: $143 · 2023: $137 · 2024: $177 · 2025: $89.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $402.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $256.12 | 2021-2025 | |
| Hologic Sales and Service, LLC | $71.35 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Bayer Healthcare Pharmaceuticals INC. | $64.16 | 2022-2023 | |
| Avion Pharmaceuticals | $54.36 | 2021 | |
| Exeltis, USA INC. | $52.20 | 2021-2024 | Slynd |
| Evofem Biosciences, INC. | $42.00 | 2021 | |
| Therapeuticsmd, INC. | $32.29 | 2021-2022 | |
| Coopersurgical, INC. | $30.20 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Astellas Pharma US INC | $28.69 | 2024 | Veozah |
| Myovant Sciences INC. | $28.25 | 2021 | |
| Merck Sharp & Dohme LLC | $27.47 | 2021-2024 | Gardasil, Gardasil 9 |
| Viiv Healthcare Company | $26.41 | 2024 | Apretude |
| Mayne Pharma Commercial LLC | $22.60 | 2025 | |
| Sumitomo Pharma America, INC. | $20.25 | 2023 | Myfembree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Burdi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.